Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Ketone Ester voor de Behandeling van Acuut Hartfalen (KETO-AHF)

4 november 2026 bijgewerkt door: University of Alberta

KETO-AHF: Ketone Ester voor de behandeling van acuut hartfalen: Een Vanguard Gerandomiseerd Gecontroleerd Onderzoek

Ketones have been suggested to have significant physiological effects in patients with heart failure. Potential mechanisms for these effects include energy provision for the failing heart and direct protective effects on other organs. Despite the strong physiological rationale, the acute effects of ketone therapy in patients with acute heart failure (AHF) is unclear. AHF is a major healthcare issue, with in-hospital mortality exceeding 10%. Therefore, we propose a vanguard randomized controlled trial to assess the effects of ketone esters in patients with AHF. Sixty patients hospitalized with AHF will be randomized to receive either 25 grams of ketone esters three times per day or a matching placebo for five days, or until death or hospital discharge. We hypothesize that ketone therapy will improve markers of systemic congestion and heart failure symptoms. Primary endpoint will be changes in NT-proBNP levels during therapy. Secondary endpoints will be KCCQ scores, and hemodynamic profile as assessed by echocardiogram. Exploratory endpoints will clinical outcomes including mortality, need for intensive care unit admission, among others.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Gedetailleerde beschrijving

KETO-AHF (Ketone Ester for Treatment of Acute Heart Failure) is a single-site, double-blind, randomized, placebo-controlled vanguard clinical trial evaluating the feasibility, safety, and preliminary efficacy of exogenous ketone ester therapy in adults hospitalized with acute heart failure (AHF). The trial is conducted as a domain within the Heart Failure Efficacy and Research Trial (HEART) Platform master protocol framework.

Adults (≥18 years) admitted with a primary diagnosis of acute heart failure will be screened and enrolled within 48 hours of hospital admission. Eligible participants must have dyspnea and clinical evidence of congestion and meet protocol-specified laboratory and clinical criteria, including elevated NT-proBNP and adequate kidney function (eGFR >15 mL/min/1.73m²). Key exclusions include type 1 diabetes mellitus, dialysis dependence, inability to tolerate enteral therapy, and need for advanced mechanical circulatory support or inopressor therapy.

Participants will be randomized 1:1 to receive ketone ester therapy or matching placebo for up to 5 consecutive days (or until hospital discharge or death), in addition to standard-of-care acute heart failure management. Randomization will occur through a centralized web-based system using stratified randomization by sex, and both participants and study staff will remain blinded to allocation.

The investigational intervention is KetoneAid MonoEster (D-β-hydroxybutyrate bonded to R-1,3-butanediol), administered orally or enterally at 25 g three times daily (total 75 g/day). The placebo arm receives a taste- and appearance-matched placebo administered on the same schedule. Study drug administration occurs after meals with flexibility to accommodate clinical care.

The primary endpoint is change in NT-proBNP over the treatment period. Secondary outcomes include change in heart failure symptoms using the Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score and change in echocardiographic measures of cardiac function. Exploratory outcomes include glycemic control and insulin requirements, renal function, daily fluid balance adjusted for diuretic dose, and clinical outcomes through 30 days including mortality and days alive and out of hospital. The vanguard design also evaluates feasibility outcomes to inform a subsequent full-scale trial, including consent rate, representation of women, intervention adherence, and follow-up completeness.

Safety monitoring includes daily clinical assessment and laboratory monitoring (including acid-base measures), with predefined adverse events of special interest and stopping rules. An independent Data Safety Monitoring Committee (DSMC) reviews safety data at prespecified enrollment intervals.

Studietype

Ingrijpend

Inschrijving (Geschat)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Justin Ezekowitz, MD
  • Telefoonnummer: 780-492-0712
  • E-mail: jae2@ualberta.ca

Studie Contact Back-up

Studie Locaties

    • Alberta
      • Edmonton, Alberta, Canada
        • University of Alberta

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Domain-Specific Inclusion Criteria:

  1. Primary diagnosis of AHF with dyspnea on exertion or at rest, and at least two of the following: congestion on chest radiograph, rales on chest auscultation, clinically relevant edema, or an elevated jugular venous pressure [21]
  2. Admitted to the hospital for less than 48 hours
  3. Estimated glomerular filtration rate above 15 mL/min/1.73m²
  4. NT-proBNP ≥ 1000 pg/ml

Domain-Specific Exclusion Criteria:

  1. Type 1 diabetes mellitus
  2. Patients on mechanical circulatory support
  3. Patients on more than one inotrope or on inopressors
  4. Patients on dialysis
  5. Patients with non-functioning enteral tracks

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: KetoneAid MonoEster

Intervention Name: KetoneAid MonoEster Formulation: D-Beta Hydroxybutyrate bonded to R 1,3 Butanediol Dosing: 25 grams, three times per day Administration: Oral or enteral route Duration: 5 consecutive days, or until hospital discharge or death

Participants randomized to the intervention arm will receive KetoneAid MonoEster (D-β-hydroxybutyrate bonded to R-1,3-butanediol) administered orally or enterally at a dose of 25 g three times daily (total 75 g/day) for up to 5 consecutive days (or until discharge or death), in addition to standard of care acute heart failure management.

Placebo-vergelijker: Placebo

Matching placebo, also provided by KetoneAid, with similar administration instructions.

Participants randomized to the control arm will receive a matching placebo administered orally or enterally three times daily for up to 5 consecutive days (or until discharge or death), in addition to standard of care acute heart failure management.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in NT-proBNP
Tijdsspanne: Baseline to Day 5 (or hospital discharge if earlier)

Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) level over the 5-day intervention period comparing ketone ester versus placebo.

Baseline to Day 5 (or hospital discharge if earlier)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS)
Tijdsspanne: Baseline to Day 5 (or hospital discharge if earlier)

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score from baseline to Day 5 comparing treatment groups.

The Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) ranges from 0 to 100, where higher scores indicate fewer heart failure symptoms and better health status, and lower scores indicate more severe symptoms and worse health status.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Left Ventricular Ejection Fraction (LVEF)
Tijdsspanne: Baseline to Day 5 (or hospital discharge if earlier)

Change in left ventricular ejection fraction from baseline to Day 5 comparing ketone ester versus placebo.

Left ventricular ejection fraction is expressed as a percentage (%), with higher values indicating better systolic function.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Mitral Inflow E/e' Ratio
Tijdsspanne: Baseline to Day 5 (or hospital discharge if earlier)

Change in mitral inflow E/e' ratio from baseline to Day 5 comparing ketone ester versus placebo.

E/e' ratio is a unitless measure of left ventricular filling pressure. Higher values indicate higher estimated filling pressures and worse diastolic function.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Stroke Volume
Tijdsspanne: Baseline to Day 5 (or hospital discharge if earlier)

Change in stroke volume from baseline to Day 5 comparing ketone ester versus placebo.

Stroke volume is measured in milliliters (mL). Higher values indicate greater forward blood flow per heartbeat.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Tricuspid Annular Plane Systolic Excursion (TAPSE)
Tijdsspanne: Baseline to Day 5 (or hospital discharge if earlier)

Change in tricuspid annular plane systolic excursion from baseline to Day 5 comparing ketone ester versus placebo.

TAPSE is measured in millimeters (mm). Higher values indicate better right ventricular systolic function.

Baseline to Day 5 (or hospital discharge if earlier)

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in serum creatinine
Tijdsspanne: Baseline to Day 5 (or discharge if earlier)

Change in renal function measured by serum creatinine over the intervention period.

Baseline to Day 5 (or discharge if earlier)
Insulin requirements
Tijdsspanne: Day 1 through Day 5 (or discharge if earlier)

Total insulin administered during the inpatient intervention period.

Day 1 through Day 5 (or discharge if earlier)
Glycemic control
Tijdsspanne: Day 1 through Day 5 (or discharge if earlier)

Daily blood glucose measurements during the intervention period.

Day 1 through Day 5 (or discharge if earlier)
Days Alive and Out of Hospital
Tijdsspanne: 30 days

Number of days alive and out of hospital through Day 30 after randomization.

30 days
All-cause mortality
Tijdsspanne: 30 days

All-cause mortality through Day 30 after randomization.

30 days
Major Adverse Kidney Events
Tijdsspanne: 30 days

Composite kidney outcome through Day 30, including death, new renal replacement therapy, or persistent renal dysfunction.

30 days
Daily Net Fluid Balance Adjusted for Loop Diuretic Dose
Tijdsspanne: Day 1 through Day 5 (or hospital discharge if earlier)

Daily net fluid balance during the inpatient intervention period (Day 1 through Day 5 or hospital discharge if earlier), adjusted for total loop diuretic dose administered.

Net fluid balance will be calculated as total fluid intake minus total fluid output and normalized to loop diuretic dose received during the same period.

Day 1 through Day 5 (or hospital discharge if earlier)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Fernando G Zampieri, MD, PhD, University of Alberta

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 januari 2027

Primaire voltooiing (Geschat)

1 juli 2027

Studie voltooiing (Geschat)

1 maart 2028

Studieregistratiedata

Eerst ingediend

15 januari 2026

Eerst ingediend dat voldeed aan de QC-criteria

19 februari 2026

Eerst geplaatst (Werkelijk)

25 februari 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • KETO-01

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren